Results for “National Commission on Fiscal Responsibility and Reform”

…4 28 32 36 40 Quarters After Recession Trough Data as of December 2016. Source: Investment Strategy Group, Bloomberg, National Bureau of Economic Research. In our 2016 Outlook and our 2016 Insight report, Walled In: China’s Great Dilemma, we stated that China was unlikely to h...

…vernment officials in order to win a series of liquefied natural gas construc- tion projects.” Together, the four multi-national cor- porations and the Japanese trading company paid a combined $1.7 billion in civil and criminal sanctions for their decade-long bribery scheme. In a...

…d. 2d 789 [32] [33] [34] involved in those attacks. 18 U.S.C.A. § 2339A(b). Cases that cite this headnote War and National Emergency @ Private Remedies Allegation that defendant funneled money to terrorist organization responsible for September 11th attacks, through charit...

…Michel — GP, Nautilus Ventures. Award-winning photographer. Fmr CEO, Affinity Labs. Fmr CEO, Military.com. Boards: International Data Group, Dale Carnegie, Kixeye, Castlight Health, USO, Marine Corps University Foundation. Katie Mitic — Fmr Head of Platform Marketing, Facebook....

…les. Capital accumulation does not exist. Any attempt lowers consumption with no growth to show for it. Keep track of national wealth including human capital by my method here, and also by Petty’s of 1664, 1676 and 1685. What would we think of corporate management that added up...

…nomist decide which version is more useful. Mine, at least, correctly describes those same four years as losing ones. National Accounts Overall It seems to me that national accounts are doing nothing wrong except in modeling the depreciation curve from misleading sales evidenc...

…isconduct once again. ° The incident happened at a dinner held at the Melbourne Zoo as part of the Australian Skeptics National Convention, where you were a featured speaker. ° With conference delegates chatting over drinks, a woman asked you for a celebrity selfie. ° As the w...

…Looking back over his first term in office Obama can point to some major gains. These include funding increases for the National Institutes of Health's (NIH) stem cell initiatives, and greater investor interest in the wider field of regenerative medicine including the use of adul...

… March 18 Director Nisbet testifies before the House Oversight and Government Reform’s Information Policy, Census, and National Archives Subcommittee hearing on “Administration of the Freedom of Information Act: Current Trends” 40 50 60 70 80 March 23 OGIS holds its first tr...

…ed therapeutically. This year the European Commission gave 144 million euros to develop 200 new therapies and the 32 National Institute of Health allocated $3.5 billion to research orphan diseases. Yet some diseases are so rare that they remain stepchildren even among orphans....

…A Company A is a Delaware corporation with its principal offices in the United States and whose shares are listed on a national U.S. exchange. Company A is considering acquiring Foreign Company, which is not an issuer or a domestic concern. Foreign Company takes no actions withi...

lose their entire principal investment. Past performance is not necessarily a guide to future performance. Levels and basis for taxation may change. This report may contain a short-term trading idea or recommendation, which highlights a specific near-term cata lyst or event imp...

…es, John Micklethwait and Matthew Bishop at the Economist, Josh Tyrangiel at Businessweek, as well as a handful of international correspondents. Ideally, the first few encounters would be at dinners and events that we organize in New York and internationally, which could be follo...

01/26/10 The 2010 planning landscape: NO estate tax, GST or basis adjustment rules; what 2010-01 Congress may do; possible constitutional “due process” challenge; what can go wrong when documents are wrong about how property is titled (Beudert-Richard v. Richard) 2009 12/22/09...

Journal of Medicine editorial (November 2013), where Janet Woodcock, MD, the FDA’s Director of the Center for Drug Evaluation and Research and other senior FDA staff members as co-authors, discussed the FDA’s new breakthrough therapy designation that can be granted to expedite th...